NPPB and heart failure: A multicenter, prospective, randomized, controlled trial–Baroreflex Activation Therapy for Heart Failure (BeAT-HF, NCT02627196)–showed that in the group of 264 patients with the FDA-approved enrolment criteria for BAT (EF ≤ 35%, NT-proBNP < 1.600 pg/mL, NYHA functional class III and without Class I indication for CRT), BAT is a safe procedure that significantly improves quality of life, exercise capacity and functional status, while it decreases NT-proBNP and reduces the number of HF hospitalizations per year.